Overview

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This trial is a multi-center, open-label, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of Cethrin in two types of spinal cord injury patients: those with a complete cervical injury or a complete thoracic injury. Dose levels from 0.3 mg - 9 mg of Cethrin will be administered.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated